Scientific Sessions 2025  /  Shifting Paradigms in Lipid Management for ASCVD Risk  /  Lower LDL-C, for Longer? Defining the Optimal Timing and Intensity of Lipid-Lowering Therapy in Primary Prevention
Logo

American Heart Association

  65
  0

Final ID:

Lower LDL-C, for Longer? Defining the Optimal Timing and Intensity of Lipid-Lowering Therapy in Primary Prevention

  • Blumenthal, Roger  ( Roger Blumenthal , Baltimore , Maryland , United States )
    • Author Disclosures:
    Roger Blumenthal: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Shifting Paradigms in Lipid Management for ASCVD Risk

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Main Event

More abstracts on this topic:
Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, for Lowering LDL Cholesterol in Adults with or At-Risk for ASCVD: The Phase 3 CORALreef Lipids Trial

Navar Ann Marie, Mendizabal Geraldine, Nuez Llota Julio, Zhu Pengfei, Zhuo Min, Ballantyne Christie, Mikhailova Elina, Catapano Alberico, Banka Puja, Blom Dirk, Cadena Alberto, Kourpanidis Susan, Lepor Norman, Tsukamoto Kazuhisa

The ODYSSEY of Lipid Lowering: Navigating the Growing Array of Therapeutics for LDL-C Reduction

Tokgozoglu Lale

More abstracts from these authors:
Optimizing Lipid Management for Cardiovascular Prevention

Blumenthal Roger, Orringer Carl

Is There a Role for CAC in Severe Hypercholesterolemia? No Way!

Blumenthal Roger, Michos Erin, Gianos Eugenia

You have to be authorized to contact abstract author. Please, Login
Not Available